Abstract
This study evaluated the cost effectiveness of bortezomib in relapsed, refractory myeloma, relative to best supportive care (BSC) and thalidomide. Data were derived from the phase 2 pivotal study of bortezomib, a Delphi panel of six myeloma thought leaders, and published literature. Objective assumptions regarding treatment choices and consequences (response and complications), and actual cost data were used. Bortezomib was found to be cost effective relative to BSC and thalidomide. Sensitivity analyses demonstrated the robustness of the results. These data suggest that bortezomib provides a cost-effective treatment option and the best value (in terms of cost/life-yr gained) among the currently available therapeutic options for relapsed, refractory myeloma.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 52-61 |
| Number of pages | 10 |
| Journal | Managed care interface |
| Volume | 17 |
| Issue number | 9 |
| State | Published - Sep 2004 |
ASJC Scopus subject areas
- Health Policy
